Historical GLP-1 and downstream commercial research. No current market claim is adopted.

Why now

Review archival scope only. Preserve the existing closure date, reason, history and calls; do not reconstruct unreviewed historical thesis details.

In scope

Identity, topic and existing closed disposition

Out of scope

Fresh thesis validation · Reopening or regrading historical calls

Expected horizon

Historical window; exact original timing remains in the archive and is not re-established by this review.

What supports it

No fresh supporting-evidence verdict; original source history is preserved.

What would break it

No live claim to invalidate; a new case requires fresh evidence and its own failure tests.

Next review On condition · No standing review. A user-requested historical audit or a new evidence-backed successor is required.

Closed 2026-05-19 · Retired with verdict in the R12 perspective-refresh fanout. The HIMS pivot vehicle is disproven at the catalyst level — the semaglutide shortage ended (Feb 2025), the FDA shut large-scale GLP-1 compounding through 2026 (a 2026-04-30 proposal to exclude semaglutide/tirzepatide/liraglutide from the 503B Bulks List), and the Novo Nordisk branded-Wegovy partnership collapsed into a patent suit + DOJ referral; HIMS Q1 2026 swung to a $92M net loss and the stock is -68% from its high. CVS does not rescue the thesis (its +26% run is an unrelated Aetna medical-loss-ratio turnaround; CVS Caremark gatekeeps GLP-1s). The durable 'channel beats SKU' idea survived but rotated to LillyDirect/Amazon/Walmart/LifeMD — no clean pure-play equity vehicle. See _beta/perspectives/2026-05-03-protein-economy/log.md 2026-05-19 entry.